Understanding and overcoming treatment resistance in genitourinary cancers
Molecular origins and evolution to treatment resistance in genitourinary cancers
This work aims to understand why genitourinary cancers like prostate and bladder cancer stop responding to treatment, helping us find new ways to fight them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11163223 on NIH RePORTER |
What this research studies
Our team is looking closely at genitourinary cancers, including prostate, bladder, kidney, and testicular cancers, to figure out why they sometimes become resistant to current treatments. We use advanced computer analysis and laboratory methods, always keeping the patient's experience at the center of our work. This helps us uncover the specific molecular changes that allow cancers to resist therapies. By understanding these changes, we hope to develop new treatment strategies and identify which patients might benefit most from them.
Who could benefit from this research
Good fit: Patients with genitourinary cancers, such as prostate, bladder, kidney, or testicular cancer, who have experienced treatment resistance, are the focus of this research.
Not a fit: Patients whose cancers have not yet developed resistance to current therapies may not directly benefit from this specific research focus on resistance mechanisms.
Why it matters
Potential benefit: If successful, this work could lead to new drug discoveries and better ways to match patients with the most effective treatments for genitourinary cancers.
How similar studies have performed: Previous work by this team has led to discoveries about chemosensitivity in bladder and testes cancers and understanding androgen inhibitor resistance in prostate cancer, creating new drug discovery paradigms.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Park, Jihye — Dana-Farber Cancer Inst
- Study coordinator: Park, Jihye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.